Page last updated: 2024-08-24

irinotecan and adamantane

irinotecan has been researched along with adamantane in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, YC; Chern, YT; Chi, CW; Lee, JY; Wang, JJ	1

Other Studies

1 other study(ies) available for irinotecan and adamantane

Article	Year
The antitumor effect of a novel differentiation inducer, 2, 2-Bis (4-(4-amino-3-hydroxyphenoxy) phenyl) adamantane (DPA), in combinatory therapy on human colon cancer. International journal of oncology, 2006, Volume: 28, Issue:4 Topics: Adamantane; Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Blotting, Western; Cadherins; Camptothecin; Carcinoembryonic Antigen; Catenins; Cell Adhesion Molecules; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Delta Catenin; Dose-Response Relationship, Drug; Drug Synergism; Fibronectins; G1 Phase; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Mice; Mice, Inbred ICR; Mice, Nude; Phosphoproteins; Resting Phase, Cell Cycle; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2006

Article

Year

The antitumor effect of a novel differentiation inducer, 2, 2-Bis (4-(4-amino-3-hydroxyphenoxy) phenyl) adamantane (DPA), in combinatory therapy on human colon cancer.

International journal of oncology, 2006, Volume: 28, Issue:4

Topics: Adamantane; Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Blotting, Western; Cadherins; Camptothecin; Carcinoembryonic Antigen; Catenins; Cell Adhesion Molecules; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Delta Catenin; Dose-Response Relationship, Drug; Drug Synergism; Fibronectins; G1 Phase; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Mice; Mice, Inbred ICR; Mice, Nude; Phosphoproteins; Resting Phase, Cell Cycle; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2006